Survival and immunophenotypes of patients with acute leukaemia treated in a hospital in Chiclayo, Peru
<ns3:p>Abstract* Objectives To determine the overall survival and immunophenotypes of patients with acute leukemia from a hospital in Chiclayo, Peru, during the period 2015-2019. Methods Observational research was conducted, analysing a total of 168 samples from patients diagnosed with acute leukemia, evaluating overall survival in the different types of leukemia at 5 years of follow-up using Kaplan-Meier curves. Results The overall survival for B-cell Acute Lymphoblastic Leukemia (B-ALL) was found to be 52.7% at 5 years of follow-up, while for T-Acute Lymphoblastic Leukemia (T-ALL), it was 50% at 2 years. The overall survival for non-promyelocytic Acute Myeloid Leukemia (AML) was 53.3% at 3 years of follow-up, and for promyelocytic leukemia, it was 66.7% at 3 years. The predominant immunophenotype was B-ALL, which represented 77.38%, while AML represented the remaining cases. Conclusions The overall survival of lymphoid leukemia was superior to that of myeloid leukemia. The most frequent aberration in B-ALL was the hyperexpression of CD10, while the absence of antigens was noted in T-ALL. The most frequent aberration in promyelocytic leukemia was the hyperexpression of CD13, and for non-promyelocytic leukemia, asynchronisms and lineage infidelity were observed.</ns3:p>
Authors
- Lizzie Karen Becerra-Gutiérrez (ORCID: https://orcid.org/0000-0001-8243-7932)
- Francisco James León Trujillo (ORCID: https://orcid.org/0000-0003-1060-5938)
- Andres Galindo-Céspedes
- Stalin Tello-Vera
- Juan De Dios Juárez-Ynoñan
- Rossana Verónica Mendoza-López
Institutions
- Instituto do Câncer do Estado de São Paulo (BR)
- Universidad Andina del Cusco (PE)
- Universidad Nacional Pedro Ruíz Gallo (PE)
- Universidad de Lambayeque (PE)
Publication Details
- Journal
- F1000Research
- Published
- 2026-01-06
- DOI
- https://doi.org/10.12688/f1000research.170288.1
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00